Female sexual dysfunction: a focus on flibanserin

Area of Science:

• Pharmacology
• Women's Health
• Sexual Medicine

Background:

• Female sexual dysfunction (FSD) affects approximately 40% of women, with limited FDA-approved treatment options.
• Low sexual desire, now classified as female sexual interest/arousal disorder (FSIAD), causes significant distress and interpersonal difficulties.
• Healthcare professionals (HCPs) play a crucial role in identifying FSD and initiating sensitive discussions about sexual health.

Purpose of the Study:

• To provide an overview of FSD types, causes, and the role of flibanserin as a treatment.
• To highlight the importance of HCPs in patient assessment and counseling for FSD.
• To review assessment tools and strategies for discussing sexual health concerns with patients.

Main Methods:

• Review of flibanserin's efficacy in clinical studies.
• Analysis of patient or provider-administered assessment tools for FSD.
• Discussion of patient counseling strategies for sexual health.

Main Results:

• Flibanserin demonstrated efficacy in clinical studies, showing increased scores on the Female Sexual Function Index (FSFI).
• Improvements were noted in overall sexual function and specifically in the desire domain.
• The study indicates flibanserin's benefit in addressing low sexual desire.

Conclusions:

• Flibanserin is the first FDA-approved medication for FSD, specifically targeting low sexual desire.
• HCPs should proactively identify and discuss FSD concerns with patients.
• Further research in diverse populations is needed, but flibanserin shows promise for improving female sexual function.